CHANGZHOU QIANHONG BIOPHARMA CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.8 CNY | +0.69% |
|
+0.69% | -1.36% |
Valuation
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,862 | 6,181 | 8,012 | 7,525 | 7,278 | - | - |
| Enterprise Value (EV) 1 | 5,862 | 6,181 | 8,012 | 7,525 | 7,278 | 7,278 | 7,278 |
| P/E ratio | 21.8 x | 32.2 x | 25 x | 42 x | 24.9 x | 19.5 x | 16.8 x |
| Yield | - | - | - | 2.04% | 3.1% | 1.81% | 4.14% |
| Capitalization / Revenue | 3.5 x | - | - | 4.15 x | 3.85 x | 3.01 x | 2.81 x |
| EV / Revenue | 3.5 x | - | - | 4.15 x | 3.85 x | 3.01 x | 2.81 x |
| EV / EBITDA | 15.9 x | - | - | 27.1 x | 16.6 x | 13.8 x | 11.5 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 2.51 x | - | - | 3.07 x | 2.84 x | 2.54 x | 2.47 x |
| Nbr of stocks (in thousands) | 1,279,975 | 1,279,800 | 1,279,800 | 1,279,800 | 1,254,800 | - | - |
| Reference price 2 | 4.580 | 4.830 | 6.260 | 5.880 | 5.800 | 5.800 | 5.800 |
| Announcement Date | 2/27/20 | 4/22/22 | 4/14/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,675 | - | - | 1,814 | 1,890 | 2,419 | 2,589 |
| EBITDA 1 | 368.1 | - | - | 277.3 | 439 | 525.6 | 634 |
| EBIT 1 | 300.2 | - | - | 204.4 | 344 | 434.3 | 504 |
| Operating Margin | 17.92% | - | - | 11.26% | 18.2% | 17.95% | 19.47% |
| Earnings before Tax (EBT) 1 | 300.5 | - | - | 203.5 | 338 | 434.5 | 503.5 |
| Net income 1 | 262.6 | 181.1 | 323.4 | 181.9 | 299.9 | 382.6 | 443.5 |
| Net margin | 15.67% | - | - | 10.02% | 15.86% | 15.82% | 17.13% |
| EPS 2 | 0.2100 | 0.1500 | 0.2500 | 0.1400 | 0.2333 | 0.2975 | 0.3450 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.1200 | 0.1800 | 0.1050 | 0.2400 |
| Announcement Date | 2/27/20 | 4/22/22 | 4/14/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 10.7% | - | - | 7.47% | 11.4% | 13.1% | 14.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | 11% | 11.5% | 13.1% |
| Assets 1 | - | - | - | - | 2,726 | 3,327 | 3,385 |
| Book Value Per Share 2 | 1.820 | - | - | 1.920 | 2.040 | 2.290 | 2.350 |
| Cash Flow per Share 2 | 0.1300 | - | - | 0.4200 | 0.3700 | 0.4300 | 0.3000 |
| Capex 1 | 99 | - | - | 68 | 154 | 92 | 154 |
| Capex / Sales | 5.91% | - | - | 3.75% | 8.15% | 3.8% | 5.95% |
| Announcement Date | 2/27/20 | 4/22/22 | 4/14/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.8
CNY
Average target price
6.12
CNY
Spread / Average Target
+5.52%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.36% | 1.01B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 002550 Stock
- Financials Changzhou Qianhong Biopharma CO.,LTD
